◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 2552

Hua Medicine (Shanghai) Ltd. (2552) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-10

Hua Medicine (Shanghai) Ltd. (2552) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Shanghai, China with about 328 employees. Its market capitalization is roughly CNY 3 billion. In the fiscal year ended 2025-12-31, 2552 reported CNY 493M in revenue and CNY 1.1B in net income.

Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China.

Interactive charts & full statements →

2552 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total RevenueCNY 493MCNY 256MCNY 77MCNY 18M
Gross ProfitCNY 280MCNY 125MCNY 37MCNY 8M
Operating Income (EBIT)(CNY 136M)(CNY 353M)(CNY 289M)(CNY 241M)
Net IncomeCNY 1.1B(CNY 250M)(CNY 211M)(CNY 204M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2552 Free Cash Flow History

2552 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-31
Total AssetsCNY 1.5BCNY 1.5BCNY 1.7BCNY 1.1B
Total LiabilitiesCNY 463MCNY 1.7BCNY 1.6BCNY 842M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2552 viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

← 2551All “0-9” companies2553 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.